Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 10  |  Issue : 7  |  Page : 155--159

Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation


Xiao Zhao1, Guangqin Zhu2, Huoming Chen3, Ping Yang4, Fang Li5, Nan Du1 
1 Department of Medical Oncology, Affiliated Hospital of PLA General Hospital, Beijing, China
2 Department of Medical Oncology, General Hospital of the Air Force of People's Liberation Army, Beijing, China
3 Department of Medical Oncology, Second Artillery General Hospital of People's Liberation Army, Beijing, China
4 Department of Medical Oncology, Navy General Hospital of People's Liberation Army, Beijing, China
5 Department of Medical Oncology, General Hospital of People's Liberation Army, Beijing, China

Correspondence Address:
Fang Li
Cancer Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing-100853
China
Nan Du
Department of Medical Oncology, Affiliated Hospital of PLA General Hospital, No. 51 Fucheng Road, Beijing 100 048
China

Objective: This study aimed to investigate the potential use of icotinib as first-line treatment to prevent brain metastasis from advanced lung adenocarcinoma. Patients and Methods: This investigation was designed as a retrospective nonrandomized controlled study. Enrolled patients received either icotinib or traditional chemotherapy as their first-line treatment. The therapeutic efficacy was compared among patients with advanced (stages IIIB and IV) lung adenocarcinoma with epidermal growth factor receptor (EGFR)-sensitive mutation. The primary endpoint was the cumulative incidence of brain metastasis, whereas the secondary endpoint was overall survival (OS). Death without brain metastasis was considered a competitive risk to calculate the cumulative risk of brain metastasis. Survival analysis was conducted using the Kaplan-Meier method and statistical significance were determined using the log-rank test. Results: The present study included 396 patients with 131 in the icotinib group and 265 in the chemotherapy group. Among those with EGFR-sensitive mutation, the cumulative risk of brain metastasis was lower in the icotinib group than in the chemotherapy group. However, no significant difference in OS was observed between the two groups. Conclusion: Icotinib can effectively reduce the incidence of brain metastasis and therefore improve prognosis in advanced lung adenocarcinoma patients with EGFR-sensitive mutation.


How to cite this article:
Zhao X, Zhu G, Chen H, Yang P, Li F, Du N. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.J Can Res Ther 2014;10:155-159


How to cite this URL:
Zhao X, Zhu G, Chen H, Yang P, Li F, Du N. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. J Can Res Ther [serial online] 2014 [cited 2020 Aug 12 ];10:155-159
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2014;volume=10;issue=7;spage=155;epage=159;aulast=Zhao;type=0